Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Longphre, E. Burmeister Getz, W. M. Foster, M. King, A. Innes, O. Schmidt, R. Fuller (Berkeley, CA, Durham, NC, United States Of America; Edmonton, AB, Canada; Edinburgh, Scotland, Nottingham, England, United Kingdom). Use of a prostasin antagonist, AER 002, in obstructive lung disease: results of two phase 2 clinical trials in CF and COPD. Eur Respir J 2008; 32: Suppl. 52, 3167

Member's Comments

No comment yet.

Related content which might interest you: Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Characteristics of COPD in never smokers: results from the international burden of obstructive lung disease (BOLD) study Source: Annual Congress 2008 - Epidemiology of respiratory symptoms and COPD Year: 2008 Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Management of chronic obstructive pulmonary disease (COPD) exacerbations: results of a French cohort study Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Early phenotypes of chronic obstructive pulmonary disease (COPD) Source: International Congress 2015 – Different data in COPD Year: 2015 Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005 Population surveillance in North West Adelaide: lung function and chronic obstructive pulmonary disease (COPD) across the diabetes spectrum Source: Annual Congress 2005 - Assessing the relevance of obstructive airway diseases Year: 2005 Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Source: Eur Respir J 2003; 21: 68-73 Year: 2003 The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Comprehensive care programme for patients with chronic obstructive pulmonary disease (COPD) --- A randomized controlled trial (RCT) Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2015 Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 How can time to COPD exacerbation be delayed? A real-world study comparing two oscillating positive expiratory pressure (OPEP) devices in patients with chronic obstructive pulmonary disease (COPD) or chronic bronchitis Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Methods for therapeutic trials in COPD: lessons from the TORCH trial Source: Eur Respir J 2009; 34: 1018-1023 Year: 2009 Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 27: 972-979 Year: 2006 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Frequency of osteoporosis and pulmonary diffusing capacity in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD: points to ponder Year: 2014